FDA greenlights ICU AI for predicting fatal COVID-19 complications

A patient in a hospital bed on a ventilator
According to CLEW Medical’s validation studies, its system predicted oncoming respiratory failure or hemodynamic instability by an average of three to four hours. (Getty/sudok1)

The FDA granted an emergency authorization to CLEW Medical’s remote data monitoring system to help predict and identify COVID-19 patients under intensive care who are most at risk for respiratory failure or insufficient blood flow.

The company’s CLEWICU artificial intelligence software ingests a large range of patient data by linking to electronic medical records, connected medical devices and vital sign monitors, with no need for additional data entry by ICU staff. 

In addition to alerting providers to a patient’s potentially deteriorating condition as a diagnostic aid, the system’s real-time risk classification model also predicts which patients may not require any interventions within an eight-hour period. 

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

RELATED: FDA looks to expand remote monitoring to free up hospital space

The FDA also said the standalone CLEWICU software, based within the hospital or in the cloud, could help reduce contact between healthcare workers and COVID-19 patients through remote monitoring.

“By identifying high risk patients, prioritizing treatment based on patient acuity, and reducing the false alarm rate this likely provides better care for patients and reduces the strain on the ICU personnel,” the agency said in its letter granting the Emergency Use Authorization. 

According to CLEW’s previous validation studies, the system was able to provide true positive alerts predicting oncoming respiratory failure or hemodynamic instability by a median of three-and-a-half hours. 

The company previously submitted an application for a full 510(k) FDA clearance while the system undergoes testing at tele-ICU facilities at UMass Memorial Medical Center and the WakeMed health system in Raleigh, North Carolina.

Suggested Articles

The FDA cleared a miniaturized and disposable sensor patch designed to detect early complications from IV drug infusions.

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs.